SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Focused Visit (Care-plan review) — Frances Burney

PatientFrances Burney
Date of birth1967-06-13
IdentifiersMRN HR-EN013-SYN; SSN (made up) 000-13-9108
Document date2026-10-19
AuthorHarriet Pell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review three weeks after right mastectomy. [S]

History of Present Illness

Mrs. Burney returns three weeks after a right total mastectomy with sentinel node biopsy. The breast MRI before surgery showed a second 0.8 cm cancer at 7 o'clock, confirmed by MRI-guided biopsy, so with Dr. Marsh she chose mastectomy; she did not want reconstruction. The germline panel showed no pathogenic variant. She had general anesthesia with a pectoral nerve block, was told of each step beforehand, and went home the next morning. Her pain was 2 out of 10 by the third day; she needed no opioid at home and stopped acetaminophen at two weeks. A seroma after drain removal was aspirated once by the surgical team eleven days ago and has not returned. The pathology shows multicentric invasive ductal carcinoma, 2.6 cm and 0.8 cm, grade 2, with clear margins and 0 of 3 sentinel nodes involved. The recurrence score is 13. Dr. Marsh and the breast program's medical oncologist advise five years of anastrozole, with no chemotherapy and no radiation. She has a little numbness under the right arm and is doing her shoulder exercises. Her bone density scan this morning shows low bone mass. [S]

ElementDetail
Interval changeRight total mastectomy and sentinel node biopsy three weeks ago; seroma aspirated once
PathologypT2(m) pN0(sn), grade 2, margins clear; recurrence score 13
GeneticsNo pathogenic germline variant
PainNone at rest; no analgesics now
FunctionShoulder flexion improving; walking daily

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; energy returning
IntegumentaryNegativeWound healed; no fluid under the flap
MusculoskeletalPositiveMild tightness raising the right arm; no bone or joint pain
NeurologicalPositiveSmall patch of numbness under the right arm
GenitourinaryNegativeNo vaginal dryness or bleeding
PsychiatricNegativeRelieved and sleeping well; PHQ-2 score 1

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets (1000 mg) by mouth every 6 hours for pain after surgery, no more than 3000 mg a dayTwo tablets every 6 hoursOral route2026-09-30 to 2026-10-14completedS
Ibuprofen 400 mg oral tablet, one tablet by mouth every 8 hours with food for five days after surgeryOne tablet every 8 hours with foodOral route2026-09-30 to 2026-10-05completedS
Anastrozole 1 mg oral tablet, one tablet by mouth once daily, planned for five yearsOne tablet once dailyOral route2026-10-19activeS
Cholecalciferol (vitamin D3) 1000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-10-19activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-19Body height160cmS
2026-10-19Body weight60.9kgS
2026-10-19Body mass index (BMI) [Ratio]23.8kg/m2S
2026-10-19Systolic blood pressure122mm[Hg]S
2026-10-19Diastolic blood pressure76mm[Hg]S
2026-10-19Heart rate74/minS
2026-10-19Respiratory rate14/minS
2026-10-19Body temperature36.6CelS
2026-10-19Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-19Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
2026-10-19Cholesterol in HDL [Mass/volume] in Serum or Plasma58mg/dL>=50 mg/dLNormalS
2026-10-19Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation132mg/dL<=99 mg/dLHighS
2026-10-19Triglyceride [Mass/volume] in Serum or Plasma120mg/dL<=149 mg/dLNormalS
2026-10-1925-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma24ng/mL30-100 ng/mLLowS
2026-10-19Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-10-19DXA Lumbar spine [T-score] Bone density-1.4{T-score}>=-1LowS
2026-10-19DXA Femur [T-score] Bone density-1.7{T-score}>=-1LowS

Physical Exam

Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]

SystemFinding
GeneralWell, cheerful
Chest wallRight mastectomy scar healed; flap flat with no fluid; no erythema
Lymph nodesNo axillary or supraclavicular nodes; left breast without masses
ExtremitiesArm circumference 26.0 cm on each side 10 cm above the elbow; right shoulder flexion 150 degrees, abduction 140 degrees
MusculoskeletalNo spinal tenderness; joints without swelling (baseline before anastrozole)

Problems

ProblemClinical statusVerificationCodeProvenance
Invasive ductal carcinoma of the right breast, upper outer quadrant at 10 o'clock, presenting as a firm lump after about a year of breast ache; core biopsy: grade 2, estrogen and progesterone receptor positive, HER2 negative; clinical stage T2 N0 (cT2 cN0 M0); synthetic modern diagnosis linked to the documented 1811 breast disease and mastectomy, whose cancer diagnosis is debatedactiveconfirmed C50.411S — Synthetic diagnosis confirmed by biopsy and surgical pathology in the modern episode; whether her historical disease was cancer remains a retrospective interpretation (R).
Estrogen receptor positive status of the breast cancer (ER 95 percent, PR 70 percent)activeconfirmed Z17.0S — Synthetic receptor result; no tissue from her lifetime was examined.
Absence of the right breast after total mastectomy without reconstruction, her choiceactiveconfirmed Z90.11S — Synthetic coding of the modern mastectomy, which echoes the documented operation.
Long-term use of anastrozole as adjuvant endocrine therapyactiveconfirmed Z79.811S — Synthetic treatment status.
Low bone mass (osteopenia) on baseline DXA before anastrozole: lumbar spine T-score -1.4, femoral neck -1.7; 10-year major osteoporotic fracture risk about 8 percent (FRAX); vitamin D insufficiencyactiveconfirmed M85.80S — Synthetic finding on the baseline DXA the protocol requires for an aromatase inhibitor.
Seroma under the right mastectomy flap after drain removal, without infection; aspirated once by the breast surgery team; resolvedresolvedconfirmed L76.34S — Synthetic common complication of the synthetic mastectomy; it does not echo a documented illness.
Firm lump in the upper outer quadrant of the right breast after about a year of heavy breast ache; clinically suspicious, imaging and biopsy bookedresolvedconfirmed N63.11S — Synthetic presenting concern at the index visit, superseded by the biopsy diagnosis; the year of breast ache echoes her documented account (D).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationCancer-related history and physical examinationEvery 3 to 6 months for the first 3 yearsCompleted todayWound healed; no signs of recurrence
LaboratorySurgical pathology and recurrence scoreAfter surgeryUp to datepT2(m) pN0(sn), margins clear; recurrence score 13
Medication safetyAromatase inhibitor startAt initiationCompleted todayAnastrozole 1 mg daily started; postmenopausal for eight years, so no ovarian suppression needed
ImagingBone density (DXA)Baseline at aromatase inhibitor start, then every 2 yearsCompleted todayLumbar spine T-score -1.4, femoral neck -1.7: low bone mass
LaboratoryLipid panelPeriodically on an aromatase inhibitor, by cardiovascular riskCompleted todayTotal cholesterol 214, HDL 58, LDL 132, triglycerides 120 mg/dL
LaboratoryCalcium and vitamin D adequacyOngoing on an aromatase inhibitorCompleted today25-hydroxyvitamin D 24 ng/mL, insufficient; vitamin D3 started and calcium from food advised
Medication safetyBone-modifying agent (bisphosphonate or denosumab)When fracture risk is high, or as adjuvant therapy at higher recurrence riskNot indicatedFracture risk about 8 percent and low recurrence risk
ExaminationAromatase inhibitor joint pain and musculoskeletal reviewEvery visitCompleted todayBaseline: no joint pain
SurveyVasomotor and vaginal symptomsPeriodically on endocrine therapyCompleted todayBaseline: none
ExaminationLymphedema assessment and risk-reduction counselingEvery visitCompleted todayArm circumference 26.0 cm on each side; no swelling; counseled on early signs
ExaminationLymphedema baseline arm measurements before surgeryBefore axillary surgeryDeferredNot measured at the pre-anesthesia visit as planned, a deviation from the protocol. Today's measurements are equal on both sides, so no swelling has been missed; they serve as the baseline, and arm measurement has been added to the pre-operative checklist
ReferralPhysical therapy for shoulder movementAfter axillary surgery when movement is limitedReferredShoulder flexion 150 degrees; four sessions requested
SurveyDepression screen (PHQ-2)At periodic intervalsCompleted todayPHQ-2 score 1
LaboratoryRoutine blood counts, chemistry, liver tests, and tumor markersNot recommended in asymptomatic stage I to III survivorsNot indicatedNone ordered
ImagingCT, bone scan, or PET for distant spreadNot recommended in asymptomatic survivorsNot indicatedNo symptoms
ImagingDiagnostic mammogram of the left breastYearly after mastectomyDueIn August, one year after the diagnostic mammogram
ReferralRadiation oncologyAfter mastectomy when nodes are positive or margins are closeNot indicatedNode-negative with clear margins
ImagingEchocardiogram (LVEF)During and after trastuzumabNot indicatedNo trastuzumab or anthracycline
Self-managementSurvivorship care plan and lifestyle counselingWithin one year of treatment; lifestyle every visitCompleted todayWritten plan given; 150 minutes of activity a week, strength exercise twice a week once allowed, alcohol at or below one drink a day

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025); American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026)

Follow-up: Physical therapy for the shoulder. Adult preventive visit next week. Survivorship visit in three months. Next scheduled visit 2026-10-29: adult preventive visit. [S]